For instance, administration of mepazine or PTXF fails to reduce tumor burden in RAG1−/− animals that are devoid of B and T cells [159,167].; In addition, the therapeutic effect is lost when CD8+ T cells are depleted by a monoclonal antibody, highlighting the importance of T cells in the therapeutic potential of NF-κB inhibitors. Here, NFKB1 is linked to neoplasm.